Clarus Corp. (CLAR)

NASDAQConsumer DiscretionaryLeisureSnapshot 2026-11-04

$4.42-2.86%

Close 2026-11-04 · 1-day change

Investment OutlookAs of Nov 4, 2026

What could strengthen or challenge Clarus Corp.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

0.0%

+10% or more+5%0%−5%−10% or less

0.17 → 0.17 EPS · FY ending Dec 31, 2027 · 3 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 2 to 3; this is not the number of analysts revising. The ±10% axis is a display range.

Price, analyst earnings & P/E reference

The EPS and P/E reference is not available for CLAR yet.

Measure / period	Management expectations	Analyst expectations

Management figures unavailable.

Current consensus figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Adjusted EBITDA between $3M and $5M for 2026	Clarus aims to achieve adjusted EBITDA between $3M and $5M in 2026.	Intact	adjusted EBITDA falls below $3 million in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 of 2 supplied quarters. Management reported: “2026 Outlook The Company continues to expect fiscal year 2026 sales to range between $245 million and $255 million and now expects adjusted EBITDA to range between approximately $12 million and $13 million, or an adjusted EBITDA margin of 5.0% at the mid-point of the revenue and adjusted EBITDA ranges.” “Adjusted EBITDA in the second quarter was $7.6 million, or an adjusted EBITDA margin of 13.6%, compared to adjusted EBITDA of $(4.4) million, or an adjusted EBITDA margin of (8.0)%, in the same year-ago quarter.” Delivery assessment Nov 4, 2026
Maintain flat free cash flow in 2026	Management is stable and focused on maintaining free cash flow.	Improving	free cash flow declines significantly below prior year in FY26	Free cash flow: $636,000 FY2026-Q2; GAAP. Published target: flat free cash flow. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 2026636,000 USD · calculatedLast status assessment Nov 4, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 of 2 supplied quarters. Management reported: “Capital expenditures are expected to remain between $6 million and $7 million, consistent with the Company’s prior outlook, and free cash flow is now expected to be $6 million for the full year 2026.” “Free cash flow for the second quarter of 2026 was $0.6 million compared to an outflow of $11.3 million in the prior year quarter.” Delivery assessment Nov 4, 2026
Revenue between $245M and $255M for 2026	A primary condition in Clarus Corp.'s published investment case. The stated target is >=245 million USD.	Intact	revenue falls below $245 million in FY26	Revenue: $56.156M FY2026-Q2; GAAP. Published target: >=245 million USD. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 202656,156,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$0.17

$0.17 → $0.17 · observed estimates

FY2027 revenue$0.26B

$0.26B → $0.26B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$0.17	$258,424,250	3 / 4
2026-07-25	$0.17	$258,424,250	3 / 4
2026-07-26	$0.17	$258,424,250	3 / 4
2026-07-27	$0.17	$258,424,250	3 / 4
2026-07-28	$0.17	$258,424,250	3 / 4
2026-07-29	$0.20	$258,344,499	2 / 3
2026-07-30	$0.20	$258,344,499	2 / 3
2026-07-31	$0.17	$258,424,250	3 / 4
2026-08-01	$0.17	$258,424,250	3 / 4
2026-08-02	$0.17	$258,424,250	3 / 4
2026-08-03	$0.20	$258,344,499	2 / 3
2026-08-04	$0.20	$258,344,499	2 / 3
2026-08-05	$0.20	$258,344,499	2 / 3
2026-08-06	$0.17	$258,424,250	3 / 4
2026-08-07	$0.20	$258,344,499	2 / 3
2026-08-08	$0.17	$258,424,250	3 / 4
2026-08-09	$0.20	$258,344,499	2 / 3
2026-08-10	$0.20	$258,344,499	2 / 3
2026-08-11	$0.17	$259,016,500	3 / 4
2026-08-12	$0.20	$258,344,499	2 / 3
2026-08-13	$0.17	$259,016,500	3 / 4
2026-08-14	$0.20	$258,344,499	2 / 3
2026-08-15	$0.20	$258,344,499	2 / 3
2026-08-16	$0.20	$258,344,499	2 / 3
2026-08-17	$0.20	$258,344,499	2 / 3
2026-08-18	$0.20	$258,344,499	2 / 3
2026-08-19	$0.20	$258,344,499	2 / 3
2026-08-20	$0.17	$257,688,667	2 / 3
2026-08-21	$0.17	$257,688,667	2 / 3
2026-08-22	$0.17	$257,688,667	2 / 3
2026-08-23	$0.17	$257,688,667	2 / 3
2026-08-24	$0.17	$257,688,667	2 / 3
2026-08-25	$0.17	$257,688,667	2 / 3
2026-08-26	$0.17	$257,688,667	2 / 3
2026-08-27	$0.17	$257,688,667	2 / 3
2026-08-28	$0.17	$257,688,667	2 / 3
2026-08-29	$0.17	$257,688,667	2 / 3
2026-08-30	$0.17	$257,688,667	2 / 3
2026-08-31	$0.17	$257,688,667	2 / 3
2026-09-01	$0.17	$257,688,667	2 / 3
2026-09-02	$0.17	$257,688,667	2 / 3
2026-09-03	$0.17	$257,688,667	2 / 3
2026-09-04	$0.17	$257,688,667	2 / 3
2026-09-05	$0.17	$257,688,667	2 / 3
2026-09-06	$0.17	$257,688,667	2 / 3
2026-09-07	$0.17	$257,688,667	2 / 3
2026-09-08	$0.17	$257,688,667	2 / 3
2026-09-09	$0.17	$257,688,667	2 / 3
2026-09-10	$0.17	$257,688,667	2 / 3
2026-09-11	$0.17	$257,688,667	2 / 3
2026-09-12	$0.17	$257,688,667	2 / 3
2026-09-13	$0.17	$257,688,667	2 / 3
2026-09-14	$0.17	$257,688,667	2 / 3
2026-09-15	$0.17	$257,688,667	2 / 3
2026-09-16	$0.17	$257,688,667	2 / 3
2026-09-17	$0.17	$257,688,667	2 / 3
2026-09-18	$0.17	$257,688,667	2 / 3
2026-09-19	$0.17	$257,688,667	2 / 3
2026-09-20	$0.17	$257,688,667	2 / 3
2026-09-21	$0.17	$257,688,667	2 / 3
2026-09-22	$0.17	$257,688,667	2 / 3
2026-09-23	$0.17	$257,688,667	2 / 3
2026-09-24	$0.17	$257,688,667	2 / 3
2026-09-25	$0.17	$257,688,667	2 / 3
2026-09-26	$0.17	$257,688,667	2 / 3
2026-09-27	$0.17	$257,688,667	2 / 3
2026-09-28	$0.17	$257,688,667	2 / 3
2026-09-29	$0.17	$257,688,667	2 / 3
2026-09-30	$0.17	$257,688,667	2 / 3
2026-10-01	$0.17	$257,688,667	2 / 3
2026-10-02	$0.17	$257,688,667	2 / 3
2026-10-03	$0.17	$257,688,667	2 / 3
2026-10-04	$0.17	$257,688,667	2 / 3
2026-10-05	$0.17	$257,688,667	2 / 3
2026-10-06	$0.17	$257,688,667	2 / 3
2026-10-07	$0.17	$257,688,667	2 / 3
2026-10-08	$0.17	$257,688,667	2 / 3
2026-10-09	$0.17	$257,688,667	2 / 3
2026-10-10	$0.17	$257,688,667	2 / 3
2026-10-11	$0.17	$257,688,667	2 / 3
2026-10-12	$0.17	$257,688,667	2 / 3
2026-10-13	$0.17	$257,688,667	2 / 3
2026-10-14	$0.17	$257,688,667	2 / 3
2026-10-15	$0.17	$257,688,667	2 / 3
2026-10-16	$0.17	$257,688,667	2 / 3
2026-10-17	$0.17	$257,688,667	2 / 3
2026-10-18	$0.17	$257,688,667	2 / 3
2026-10-19	$0.17	$257,688,667	2 / 3
2026-10-20	$0.17	$257,688,667	2 / 3
2026-10-21	$0.17	$257,688,667	2 / 3
2026-10-22	$0.17	$257,688,667	2 / 3
2026-10-23	$0.17	$257,688,667	2 / 3
2026-10-24	$0.17	$257,688,667	2 / 3
2026-10-25	$0.17	$257,688,667	2 / 3
2026-10-26	$0.17	$257,688,667	2 / 3
2026-10-27	$0.17	$257,688,667	2 / 3
2026-10-28	$0.17	$257,688,667	2 / 3
2026-10-29	$0.17	$257,688,667	2 / 3
2026-10-30	$0.17	$257,688,667	3 / 3
2026-10-31	$0.17	$257,688,667	3 / 3
2026-11-01	$0.17	$257,688,667	3 / 3
2026-11-02	$0.17	$257,688,667	3 / 3
2026-11-03	$0.17	$257,688,667	3 / 3
2026-11-04	$0.17	$257,688,667	3 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-06-01	3	3
2026-07-01	2	3
2026-08-01	2	3
2026-09-01	2	3
2026-10-01	2	3
2026-11-01	2	3

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 2 Buy / Strong Buy · 3 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Oct 6–Nov 4 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Adjusted EBITDA between $3M and $5M for 2026Direct metric needs a verified mapping
Maintain flat free cash flow in 2026Free cash flow: $636,000
Revenue between $245M and $255M for 2026Revenue: $56.156M

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.5%Typical daily move · historical

Downside history

-33.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Clarus Corp. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 31, 2026

What kind of bet this is

This is a small-cap recovery story rather than a durable compounder, with a loss-making value profile and fragile earnings quality. The long-term thesis is in a watch state: management execution has improved in some areas, but recent financial performance remains well below its industry cohort.

What's priced into Clarus Corp.

CLAR is described as cheap versus peers, and the valuation score has recently fallen. The expectations gap is slightly negative, while the priced-in assessment says weak execution is reflected but not a broader stack of expensive valuation, weak execution, and turbulence.

What the fundamentals likely do

Near term, management’s 2026 goals show mixed progress: adjusted EBITDA guidance rose to $12 million to $13 million, free cash flow guidance rose to $6 million, and sales guidance was reduced to $245 million to $255 million. First-half revenue was consistent with the revised sales outlook, and second-quarter free cash flow was positive, but the business remains loss-making and recent performance is weak. The next call matters because a guidance cut would be a meaningful negative, despite three recent earnings beats.

What Clarus Corp. hinges on

The multi-year thesis hinges on management delivering its revised sales outlook while continuing progress toward its EBITDA and free cash flow goals. Near-term sector signals also matter: continued earnings strength and higher guidance from HAS, LTH, and GOLF would support the sector backdrop, while misses or lower guidance could remove that support.